212-681-1575
Sep

1

Ceritinib May Bring Another Treatment Option to Ca...

Posted by

Label: Featured News


In May, MesotheliomaHelp reported that crizotinib is better than chemotherapy in fighting brain metastasis in lung cancer patients. Now, researchers report that another drug, ceritinib, continued to improve response in patients even after they were treated with crizotinib. Researchers from Italy, reporting on the final results of a phase II clinical trial designed to test the safety and efficacy of ceritinib in non-small cell lung cancer patients who have previously been treated with chemotherapy and crizotinib, found that the response to ceritinib was nearly immediate with tumor response noted at just 1.8 months and continuing for a median of 9.7 months. Median progression-free survival was 5.7 months, median overall survival was 14.9 months, and the one-year overall survival rate was 63.8%, according to a July 18 article in Oncology
Read Full Story

Want Specific topic updates?